MX9707015A - Procedimiento para aislar galantamina. - Google Patents
Procedimiento para aislar galantamina.Info
- Publication number
- MX9707015A MX9707015A MX9707015A MX9707015A MX9707015A MX 9707015 A MX9707015 A MX 9707015A MX 9707015 A MX9707015 A MX 9707015A MX 9707015 A MX9707015 A MX 9707015A MX 9707015 A MX9707015 A MX 9707015A
- Authority
- MX
- Mexico
- Prior art keywords
- galanthamine
- produced
- isolating
- isolating galanthamine
- alzheimer
- Prior art date
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title abstract 10
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 title abstract 5
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 title abstract 5
- 229960003980 galantamine Drugs 0.000 title abstract 5
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 title abstract 5
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title abstract 5
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 title abstract 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Extraction Or Liquid Replacement (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
El objeto de la presente invencion es un procedimiento para aislar el alcaloide galantamina (formula I), la galantamina producida a través del procedimiento en cuestion, el uso de la galantamina así producida en formas galénicas, y el uso de galantamina así producida en el tratamiento de un glaucoma de ángulo estrecho, la enfermedad de Alzheimer y la dependencia del alcohol y de la nicotina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19509663.0 | 1995-03-17 | ||
DE19509663A DE19509663A1 (de) | 1995-03-17 | 1995-03-17 | Verfahren zur Isolierung von Galanthamin |
PCT/EP1996/001094 WO1996029332A1 (de) | 1995-03-17 | 1996-03-14 | Verfahren zur isolierung von galanthamin |
Publications (2)
Publication Number | Publication Date |
---|---|
MX9707015A true MX9707015A (es) | 1997-11-29 |
MXPA97007015A MXPA97007015A (es) | 1998-07-03 |
Family
ID=
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY114698A (en) | A process for the isolation of galanthamine | |
ES2114471A1 (es) | Nuevos compuestos de paroxetina y procedimiento para su preparacion. | |
IL117848A0 (en) | Novel compounds a process for their production and pharmacetical compositions containing same | |
HUT60719A (en) | Process for producing 3-aminopiperidine derivatives | |
WO2002002505A8 (en) | Compounds to treat alzheimer's disease | |
WO2002002512A3 (en) | Compounds to treat alzheimer's disease | |
UA48946C2 (uk) | Арилалкілдіазинони, спосіб їх одержання (варіанти), фармацевтичний склад, спосіб його одержання та спосіб лікування | |
WO2002002520A8 (en) | Compounds to treat alzheimer's disease | |
AU2001252958A1 (en) | Compounds and methods to treat alzheimer's disease | |
MX9701679A (es) | Derivados de piperidina como antagonistas de la neuroquinina. | |
IL132153A0 (en) | Novel compounds | |
MX9601069A (es) | Nuevas pirido /3,2-e/pirazinonas con efecto antiasmatico y procedimiento para su preparacion. | |
AU8974298A (en) | 1,4,7,10-tetraazabicyclo{8.2.2}tetradecan-2-one, a process for the preparation thereof and the use thereof for the preparation of tetraazamacrocycles | |
FI93117C (fi) | Analogiamenetelmä terapeuttisesti käyttökelpoisten 9-aminotetrahydroakridiinijohdannaisten valmistamiseksi | |
DE59707550D1 (de) | Pharmazeutische Zubereitung, die 2-Phenyl-1,2-Benzoisoelenazol-3(2H)-one enthält, für die Behandlung der Alzheimer-Krankheit | |
EP0774462A4 (en) | HETEROCYCLIC COMPOUND | |
IL125002A0 (en) | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4] diazepanes useful for the treatment of allergic diseases | |
SE9702716D0 (sv) | Substituted phenylazacycloalkanes in the treatment of cognitive disorders | |
CA2078700A1 (en) | Imidazolylmethyl-pyridines | |
DE69526452T2 (de) | Indolditerpen alkaloide | |
TW330933B (en) | Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes | |
NZ335493A (en) | Substituted 4-(6-fluoro-(1h)-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | |
TW358807B (en) | Processes and intermediates for preparing 3-(1-piperazinyl)-1,2-benzisothiazole | |
MXPA98005355A (es) | Derivados de 5-[(heteroaril) alquil]-3 -oxo-pirido [1, 2-a]bencimidazol -4-carboxamida utiles en el tratamiento de trastornos del sistema nervioso central. | |
GR3031544T3 (en) | New derivatives of pyridine or pyridazine, process for production thereof and medicaments containing these compounds |